Senior Dog Daily logo
Senior Dog Daily
Menu
The Loyal Dog Longevity Drug: What LOY-002 Is, and When You Can Actually Get It

The Loyal Dog Longevity Drug

By Sarah Bennett · Last updated October 9, 2026 · 11 min read

Every few months a wave of headlines promises a pill that will make your dog live longer, and every time, a senior dog owner who has been watching a gray muzzle creep in wants to know one thing: is this real, and can I get it? The honest answer about the Loyal dog longevity drug is yes and not yet. Loyal is a real, FDA-engaged company; its senior-dog drug, LOY-002, has cleared two of the three major hurdles the FDA requires; and it is genuinely aiming to add about a year of healthy life. But as of October 9, 2026 it is not approved and not on sale, and the version most owners read about is sometimes the wrong one for their dog.

This guide cuts through the headlines. It explains what the Loyal longevity drugs actually are, how the three of them differ, how they are supposed to work, exactly where they stand with the FDA, what they may cost, and, most importantly, what genuinely extends a senior dog's healthy years that you can do today, without waiting for a prescription that does not exist yet. We are not veterinarians; this is reported from Loyal's own announcements, FDA filings, and veterinary coverage.

What Is the Loyal Dog Longevity Drug?

Loyal (the trade name of the company Cellular Longevity) is a clinical-stage animal health company developing drugs whose stated purpose is not to treat one disease but to extend the healthy lifespan of dogs. That framing matters. The goal is not just more years; it is more good years, what researchers call healthspan, by slowing some of the biological processes that drive age-related decline.

There is not one Loyal drug. Three are in development, aimed at different dogs, and the headlines often blur them together. If you take one thing from this article, take this: find out which drug a story is talking about before you get your hopes up or write it off.

LOY-001, LOY-003, and LOY-002

LOY-001 LOY-003 LOY-002
For Large and giant breeds, 7 years and up, at least 40 lb Large and giant breeds, 5 years and up, at least 60 lb Senior dogs, 10+ years, 14 lb and up
Form Long-acting injection at the vet, every 3 to 6 months Daily pill Daily flavored tablet at home
How it works Lowers IGF-1, a growth hormone large dogs overproduce Targets the same IGF-1 over-expression Targets age-related metabolic decline
FDA stage RXE letter in 2023 RXE section completed in 2026 Further along; two of three sections cleared
On sale? No No No. Manufacturing still marked in progress

LOY-001 is built around a specific insight: through generations of breeding for size, large dogs produce more of a growth hormone called IGF-1 than they need once they are grown, and high IGF-1 is linked to their famously shorter lifespans. LOY-001 aims to lower IGF-1 toward the levels seen in smaller, longer-lived dogs. It is given as an injection by a veterinarian every few months.

LOY-002 is the one most senior dog owners actually want to know about, because it is for any senior dog of at least 14 pounds, age 10 and up, regardless of breed. It is a daily flavored tablet you would give at home, and rather than targeting one hormone, it aims to improve the metabolic health that declines with age, the same underlying deterioration that feeds arthritis, cognitive decline, heart disease, and cancer.

LOY-003 is the other large-dog drug, a daily pill rather than the injection. Loyal's owner page says "In 2026, LOY-003 completed its RXE section." That is one section. It is not the two-of-three status LOY-002 already has, and the same page still marks approval as not guaranteed.

Where It Stands With the FDA

This is where the headlines tend to outrun reality, so here is the careful version.

To reach the market, an FDA conditional approval requires three technical sections: effectiveness, safety, and manufacturing (CMC). Loyal's own status page puts it plainly: "As of December 2025, LOY-002 has completed two of the three major requirements needed for FDA conditional approval: safety and efficacy." Loyal says these drugs are being developed under the FDA Center for Veterinary Medicine's expanded conditional approval pathway, and the same page says approval is not guaranteed.

The three sections stand like this:

  • Effectiveness (RXE): Loyal's February 2025 announcement says LOY-002 received formal FDA acceptance for a reasonable expectation of efficacy.
  • Safety (TAS): Loyal's owner page says the veterinary center accepted that package in December 2025. The December 2025 sentence quoted above already counts safety as one of the two completed sections.
  • Manufacturing (CMC): still in progress. On October 9, 2026, Loyal's vet page still marked that manufacturing section in progress.

LOY-001, for large breeds, is earlier in the process. LOY-003, the large-dog pill, has an RXE section completed in 2026 and is not on sale. Because this is moving quickly, check Loyal's site for the latest status if you are reading this well after October 9, 2026.

One term worth understanding: conditional approval is not the same as full approval. It is an FDA pathway that would let Loyal sell the drug, under veterinary prescription and continued monitoring, while it keeps gathering full effectiveness data over several more years. It is a real, regulated step, not a loophole, but it means the long-term proof is still being collected even after the drug becomes available.

Behind all of this is the STAY study, which Loyal describes as the largest veterinary clinical trial in history: "1,300 dogs, across 70+ clinics nationwide", with enrollment completed in mid-2025, in the first FDA-concurred trial designed specifically to measure canine longevity. Loyal adds a detail that says something about the selection: the study "has screened over 1,500 dogs in order to enroll 1,300 eligible participants." That is a serious undertaking, and it is a big part of why this drug is treated as credible science rather than a supplement-aisle promise.

What the Loyal Dog Longevity Drug May Cost and Who Qualifies

There is no official price, because there is no approved drug to price. What exists is reporting: as of May 2026, Entrepreneur described Loyal as "on track to launch as soon as next year for around $100 a month". That "next year" is the magazine's wording from May 2026. Loyal's pages, read October 9, 2026, do not give an approval year. The $100 figure is the magazine's number.

On who qualifies, Loyal's owner page says LOY-002 is intended for dogs aged 10 and older and weighing at least 14 lb. Very small dogs are not in the current senior program, partly because tiny breeds already tend to live long lives, and partly because the trial population was defined that way.

When it does arrive, it would be a prescription dispensed through your veterinarian, not an over-the-counter purchase, and your vet would decide whether your individual dog is a sensible candidate.

What It Can and Cannot Do

Manage your expectations the way a good vet would.

What it is aiming for: roughly one additional year of healthy life for a senior dog, on average, by slowing age-related decline. That is the trial's ambition, not a guaranteed outcome for any individual dog, and "healthy" is the operative word. The point is more good time, not simply a longer slow decline.

What it is not: it is not a cure for any specific disease, not a fountain of youth, and not a reason to delay treating the problems your dog has now. A dog with untreated arthritis, dental disease, or a heart murmur needs those addressed today, with or without a longevity drug on the horizon.

It is reasonable to be both excited and patient. The science is real and the FDA engagement is real. It is also still, as of this writing, a drug you cannot buy.

What Actually Extends Your Senior Dog's Healthy Years, Right Now

No one putting "anti-aging pill" in a headline wants to lead with this: the things proven to add healthy years to a dog's life are already available, free or cheap, and within your control. The Dog Aging Project and decades of veterinary research point to the same unglamorous levers.

  • Keep her lean. Staying at a healthy weight is the single best-documented way to extend a dog's life and delay arthritis, diabetes, and heart strain. In the landmark Purina Life Span Study, lean-fed Labradors lived a median of about 1.8 years longer than their overweight littermates (13.0 versus 11.2 years).
  • Stay on top of dental disease. Oral infection is not just a mouth problem; it stresses the whole body. See senior dog dental care.
  • Keep her moving, gently. Regular, low-impact exercise preserves muscle, joints, and brain, and pairs well with the mental stimulation an aging mind needs.
  • Go to the vet twice a year. Senior dogs benefit from twice-yearly exams and baseline bloodwork, which catch the treatable diseases that hide behind aging early. Our vet visit prep checklist makes those visits count.
  • Support the joints and the diet. Evidence-supported joint supplements and a quality, appropriately portioned diet do real work over years.

None of that is as exciting as a pill. All of it is available today, and a longevity drug, when it arrives, would be an addition to this foundation, not a replacement for it.

Frequently Asked Questions

Is the Loyal dog longevity drug available yet?

No. As of October 9, 2026, LOY-002, LOY-001, and LOY-003 are not FDA approved and not on sale. LOY-002 has cleared two of the three required FDA sections, and Loyal's vet page still marks manufacturing in progress.

How much will the Loyal dog drug cost?

There is no official price yet, because the drug is not approved. Reporting in May 2026 described Loyal as "on track to launch as soon as next year for around $100 a month". That "next year" is the magazine's line from May 2026. Loyal's pages do not give an approval year. The $100 figure is the magazine's reporting. It would be a prescription dispensed through your veterinarian.

What is the difference between LOY-001 and LOY-002?

LOY-001 is for large and giant breeds and is a long-acting injection given at the vet every few months; it works by lowering IGF-1, a growth hormone large dogs overproduce. LOY-003 is the other large-dog drug, a daily pill for dogs 5 years and older weighing at least 60 pounds, and Loyal says its RXE section was completed in 2026. LOY-002 is for senior dogs aged 10 and older weighing at least 14 pounds, is a daily tablet given at home, and targets age-related metabolic decline.

How much longer could the drug make my dog live?

Loyal's stated goal for LOY-002 is roughly one additional year of healthy life on average. That is the aim of the clinical program, not a guarantee for any individual dog, and the emphasis is on healthy years rather than simply extending old age.

Is the Loyal longevity drug safe?

The FDA accepted Loyal's safety package for LOY-002 in December 2025, which is a meaningful step, but long-term safety data continues to be gathered through the STAY study and would continue after any conditional approval. As with any new medication, your veterinarian would weigh it against your specific dog's health.

What can I do for my dog's longevity while I wait?

The proven steps are available now: keep her lean, manage dental disease, maintain gentle regular exercise, see the vet twice a year with baseline bloodwork, and support joints and diet. These do more for healthy lifespan today than any product you can currently buy.

Sources

  • Loyal (Cellular Longevity), owner status page, read October 9, 2026. Source of the December 2025 two-of-three line, the December 2025 safety acceptance, and the LOY-003 RXE sentence. loyal.com
  • Loyal, vet pipeline page, read October 9, 2026. Manufacturing section still marked in progress. loyal.com/for-vets
  • Loyal, FDA acceptance of reasonable expectation of effectiveness for senior dog lifespan extension (2025). businesswire.com
  • dvm360, FDA reasonable expectation of effectiveness for large dog lifespan extension. dvm360.com
  • GoodRx Pet Health, Upcoming anti-aging drugs for dogs. goodrx.com
  • Kealy RD, Lawler DF, Ballam JM, Mantz SL, Biery DN, Greeley EH, Lust G, Segre M, Smith GK, Stowe HD. Effects of diet restriction on life span and age-related changes in dogs (Purina Life Span Study). JAVMA 2002;220:1315-1320. Authors, journal, volume and pages re-checked against the published record on 2026-09-10. PMID 11991408 (PubMed renders with JavaScript and cannot be quoted from).
  • Entrepreneur, This $100-a-Month Pill Can Extend the Life of Your Dog, May 2026. Source of the price expectation quoted above. entrepreneur.com
  • Loyal, STAY study finishes enrollment at 1,300 dogs (2025). loyal.com
  • Dog Aging Project, ongoing research on canine aging and healthspan. dogagingproject.org

Keep Reading

About the authors

Sarah Bennett writes about senior dog care from a household centered on her Border Collie, Lucy. Her concern with the Loyal dog longevity drug coverage was the gap between the headlines and the reality: the science is genuinely promising, but the most useful thing an owner can do with that excitement today is double down on the lifestyle steps that already work. She is not a veterinarian; her work is reported, sourced from company filings, FDA announcements, and veterinary coverage.

Leo Bennett is the co-author of Senior Dog Daily and Sarah's husband. The pair share research and writing duties on the site.

Sarah and Leo Bennett are pen names. Senior Dog Daily is written and checked by a small editorial team; see About.